IPM.ai

Specialty and rare diseases have undefined patient populations, with individuals who are undiagnosed or misdiagnosed, healthcare providers who are unaware of disease states and their clinical manifestations, as well as treatment journeys that are not well-understood. Until now, no one in the industry had the necessary technology, capabilities and domain expertise to help pharmaceutical and biopharmaceutical companies define, recruit and engage patients who could benefit from the commercialization of new therapies and modalities of care. Enter IPM.ai.IPM.ai is an Insights as a Service (IaaS) company that has developed the world’s first HIPAA-certified system of insight that utilizes machine learning, artificial intelligence and granular-level longitudinal analysis in conjunction with an enriched and tokenized data pool of over 300 million de-identified patients to revolutionize patient discovery, healthcare provider intelligence, key opinion leader identification, treatment journey mapping, market segmentation, study recruitment and audience engagement so that pharmaceutical and biopharma companies can successfully research, develop and commercialize life-savings therapies that lead to optimal patient outcomes quicker with less risk.